mirtazapine has been researched along with Body Weight in 18 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Excerpt | Relevance | Reference |
---|---|---|
"We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 9.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
"To investigate the effect of mirtazapine on tumor growth, food intake, body weight, and nutritional status in gemcitabine-induced mild cachexia." | 7.78 | Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts. ( Jia, L; Jiang, SM; Wu, JH, 2012) |
"To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain." | 7.74 | Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007) |
"We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 5.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
" Mirtazapine, a widely used antidepressant, induces adverse metabolic effects such as an increase in body weight." | 5.12 | Effect of mirtazapine treatment on body composition and metabolism. ( Deisenhammer, EA; Ebenbichler, CF; Engl, J; Hinterhuber, H; Kramer-Reinstadler, K; Laimer, M; Lechner-Schoner, T; Patsch, JR; Rauchenzauner, M; Strauss, R, 2006) |
"5% in mean body weight over the course of the study in the mirtazapine group that appeared to reach a plateau at 3 weeks, while no increase was observed in the placebo group." | 5.10 | The effects of mirtazapine on plasma lipid profiles in healthy subjects. ( Ekstrom, RD; Esposito, SM; Ford, AL; Golden, RN; Nicholas, LM, 2003) |
"To investigate the effect of mirtazapine on tumor growth, food intake, body weight, and nutritional status in gemcitabine-induced mild cachexia." | 3.78 | Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts. ( Jia, L; Jiang, SM; Wu, JH, 2012) |
"To investigate the effects of mirtazapine and fluoxetine, representatives of the noradrenergic and specific serotonergic antidepressant (NaSSA) and selective serotonin reuptake inhibitor (SSRI) antidepressant respectively, on body weight, ingestive behavior, locomotor activity and tumor growth of human pancreatic carcinoma xenografts in nude mice." | 3.74 | Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. ( Jia, L; Li, YY; Shang, YY, 2008) |
"To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain." | 3.74 | Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007) |
" Weight gain is the most commonly reported side-effect of mirtazapine, although there is evidence to suggest that this is not a significant problem during long-term treatment." | 2.41 | Tolerability and safety aspects of mirtazapine. ( Nutt, DJ, 2002) |
"Changes in body weight can affect the overall health of an older patient and should not be considered a normal part of the aging process." | 1.40 | Potential role of mirtazapine in underweight older adults. ( Avena-Woods, C; Hilas, O, 2014) |
"Mirtazapine is an antidepressant approved for the treatment of major depressive disorder." | 1.38 | Antidepressant use in underweight older adults. ( Avena-Woods, C; Hilas, O, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.56) | 18.2507 |
2000's | 9 (50.00) | 29.6817 |
2010's | 7 (38.89) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Flores Gutiérrez, J | 1 |
Natali, G | 1 |
Giorgi, J | 1 |
De Leonibus, E | 1 |
Tongiorgi, E | 1 |
Hilas, O | 2 |
Avena-Woods, C | 2 |
Jia, L | 2 |
Shang, YY | 1 |
Li, YY | 1 |
Riechelmann, RP | 1 |
Burman, D | 1 |
Tannock, IF | 1 |
Rodin, G | 1 |
Zimmermann, C | 1 |
Safer, DL | 1 |
Darcy, AM | 1 |
Lock, J | 1 |
Laino, CH | 1 |
Fonseca, C | 1 |
Sterin-Speziale, N | 1 |
Slobodianik, N | 1 |
Reinés, A | 1 |
Dolev, Z | 1 |
Jiang, SM | 1 |
Wu, JH | 1 |
Nutt, DJ | 1 |
Kraus, T | 1 |
Haack, M | 1 |
Schuld, A | 2 |
Hinze-Selch, D | 1 |
Koethe, D | 1 |
Pollmächer, T | 2 |
Nicholas, LM | 1 |
Ford, AL | 1 |
Esposito, SM | 1 |
Ekstrom, RD | 1 |
Golden, RN | 1 |
Schmid, DA | 1 |
Wichniak, A | 1 |
Uhr, M | 1 |
Ising, M | 1 |
Brunner, H | 1 |
Held, K | 1 |
Weikel, JC | 1 |
Sonntag, A | 1 |
Steiger, A | 1 |
Himmerich, H | 1 |
Fulda, S | 1 |
Schaaf, L | 1 |
Beitinger, PA | 1 |
Shen, J | 1 |
Chung, SA | 1 |
Kayumov, L | 1 |
Moller, H | 1 |
Hossain, N | 1 |
Wang, X | 1 |
Deb, P | 1 |
Sun, F | 1 |
Huang, X | 1 |
Novak, M | 1 |
Appleton, D | 1 |
Shapiro, CM | 1 |
Laimer, M | 1 |
Kramer-Reinstadler, K | 1 |
Rauchenzauner, M | 1 |
Lechner-Schoner, T | 1 |
Strauss, R | 1 |
Engl, J | 1 |
Deisenhammer, EA | 1 |
Hinterhuber, H | 1 |
Patsch, JR | 1 |
Ebenbichler, CF | 1 |
Jaafar, NR | 1 |
Daud, TI | 1 |
Rahman, FN | 1 |
Baharudin, A | 1 |
Peeters, BW | 1 |
van der Heijden, R | 1 |
Gubbels, DG | 1 |
Vanderheyden, PM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437] | Phase 2 | 16 participants | Interventional | 2003-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for mirtazapine and Body Weight
Article | Year |
---|---|
Tolerability and safety aspects of mirtazapine.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Body Weight; Depressive Disorder; Humans; Mians | 2002 |
6 trials available for mirtazapine and Body Weight
Article | Year |
---|---|
Phase II trial of mirtazapine for cancer-related cachexia and anorexia.
Topics: Aged; Aged, 80 and over; Anorexia; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Cachexia | 2010 |
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Body Weight; Cross-Over Studies; Cyclohexanols; | 2002 |
The effects of mirtazapine on plasma lipid profiles in healthy subjects.
Topics: Adult; Antidepressive Agents, Tricyclic; Body Weight; Cholesterol; Coronary Disease; Dose-Response R | 2003 |
Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.
Topics: Adrenocorticotropic Hormone; Adult; Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Bod | 2006 |
Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Drug Admin | 2006 |
Effect of mirtazapine treatment on body composition and metabolism.
Topics: Adipose Tissue; Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Composition; Body Fat D | 2006 |
11 other studies available for mirtazapine and Body Weight
Article | Year |
---|---|
Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.
Topics: Adolescent; Adult; Animals; Antidepressive Agents; Body Weight; Disease Models, Animal; Female; Huma | 2022 |
Potential role of mirtazapine in underweight older adults.
Topics: Aged; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Humans; Mianserin; Mirtazapine; Quali | 2014 |
Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Ca | 2008 |
Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report.
Topics: Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Female; | 2011 |
Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Dru | 2010 |
Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.
Topics: Antidepressive Agents, Tricyclic; Body Weight; Delayed-Action Preparations; Dose-Response Relationsh | 2011 |
Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Carcinoma; Cell Line, Tumor; Deoxyc | 2012 |
Antidepressant use in underweight older adults.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weigh | 2012 |
Changes in weight and glucose tolerance during treatment with mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Blood Glucose; Body Weight; Depressive Disorder; Female; Glucose T | 2006 |
Mirtazapine for anorexia nervosa with depression.
Topics: Adolescent; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Cognitive Behavioral Th | 2007 |
Effects of chronic antidepressant treatment on the hypothalamic-pituitary-adrenal axis of Wistar rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Body Weight; Corticosterone; Hippocampus; | 1994 |